Related Experiment Video
Updated: Aug 6, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
SIRT5 Attenuates Doxorubicin-Induced Acute Cardiac Injury by Modulating PHB2 Succinylation and the Mitophagic
Aihui Zeng1,2,3, Haiqiong Liu1,3, Xudong Song1,3
1Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University, NO. 253, Gongye Avenue, Guangzhou, 510282, Guangdong, People's Republic of China.
Abstract:
Doxorubicin (DOX)-induced cardiac injury remains a major limitation of chemotherapy and is closely linked to mitochondrial dysfunction, oxidative stress, and dysregulated mitophagy. Sirtuin 5 (SIRT5), a mitochondrial deacylation-related protein, has been implicated in mitochondrial homeostasis; however, its role in DOX-induced acute cardiaotoxicity is not fully understood. Here, we investigated whether SIRT5 mitigates acute DOX-induced cardiac injury by regulating prohibitin 2 (PHB2) succinylation and mitochondrial quality control. An acute DOX-induced cardiac-damaged mouse model was established (15 mg/kg for one single dose, i.p.) in male C57BL/6 mice, serum lactate dehydrogenase (LDH), cardiac troponin T (cTnT), and cardiac creatine kinase isoenzyme MB (CK-MB) were elevated, accompanied by reduced cardiac SIRT5 expression. In primary cardiomyocytes, DOX (4 µM, 24 h) downregulated SIRT5 and induced excessive ROS production and apoptosis together with altered mitophagy-related signaling. SIRT5 overexpression attenuated DOX-triggered ROS accumulation and apoptosis and reversed these mitophagy-associated alterations. Mechanistically, PHB2 succinylation was increased upon DOX exposure, whereas SIRT5 overexpression reduced PHB2 succinylation detected by PHB2 immunoprecipitation followed by pan-succinyl-lysine immunoblotting. In addition, SIRT5 showed colocalization and interaction with PHB2. Collectively, our findings suggest that SIRT5 attenuates acute DOX-induced cardiotoxicity, potentially through modulating PHB2 succinylation and the mitophagic response, highlighting the SIRT5-PHB2 axis as a candidate target for alleviating early-onset of DOX-induced cardiac injury.
Insights
Sirtuin 5 (SIRT5) protects against doxorubicin-induced cardiac injury by regulating prohibitin 2 (PHB2) succinylation and mitophagy. This highlights the SIRT5-PHB2 axis as a therapeutic target for chemotherapy-related heart damage.
Area of Science:
- Cardiovascular Biology
- Mitochondrial Medicine
- Oncology Therapeutics
Background:
- Doxorubicin (DOX) chemotherapy causes cardiotoxicity, linked to mitochondrial dysfunction and impaired mitophagy.
- Sirtuin 5 (SIRT5), a mitochondrial protein, is involved in homeostasis, but its role in DOX cardiotoxicity is unclear.
Purpose of the Study:
- To investigate if SIRT5 mitigates acute DOX-induced cardiac injury.
- To explore SIRT5's regulation of prohibitin 2 (PHB2) succinylation and mitochondrial quality control.
Main Methods:
- Established a DOX-induced cardiotoxicity mouse model and used primary cardiomyocytes.
- Analyzed serum biomarkers (LDH, cTnT, CK-MB), oxidative stress (ROS), apoptosis, and mitophagy.
- Investigated PHB2 succinylation via immunoprecipitation and immunoblotting; assessed SIRT5-PHB2 interaction.
Main Results:
- DOX elevated cardiac injury markers and reduced SIRT5 expression.
- DOX induced ROS and apoptosis, with altered mitophagy signaling, which SIRT5 overexpression attenuated.
- DOX increased PHB2 succinylation; SIRT5 overexpression reduced it and showed colocalization/interaction with PHB2.
Conclusions:
- SIRT5 attenuates acute DOX-induced cardiotoxicity.
- The SIRT5-PHB2 axis modulates PHB2 succinylation and mitophagy, offering a potential therapeutic target for early-onset DOX cardiotoxicity.
